Study Cohort (No.=90) Study Cohort Study Cohort P value
Significant QTc Prolongation Significant QTc Prolongation
No (No.=48) Yes (No.42)
Male, % 55 (61) 26 (60) 27 (61) 0.83
Age, mean (SD) 67 ± 11 67 ± 12 67 ± 11 0.91
BMI, mean (SD), kg/m2 30 ± 5 29 ± 4 30 ± 5 0.44
Atrial flutter 7 (8) 5 (11) 2 (4) 0.25
Heart Rate in AF, mean (SD), bpm 80 ± 20 78 ± 21 82 ± 20 0.56
Ischemic Heart Disease, % 19 (21) 8 (16) 12 (27) 0.30
CHF, % 30 (36) 12 (29) 18 (43) 0.25
TEE, % 63 (70) 31 (63) 32 (76) 0.67
EF, mean (SD), % 52 ± 12 54 ± 12 49 ± 14 0.11
LA size, mean (SD), cm 4.5 ± 0.4 4.5 ± 0.5 4.4 ± 1 0.64
Mitral regurgitation, % 56 (62) 23 (48) 33 (79) 0.049
Mitral stenosis, % 14 (15) 7 (15) 7 (17) 0.86
Aortic stenosis, % 12 (13) 6 (14) 6 (15) 0.87
SPAP, mean (SD), mmHg 34 ± 8 34 ± 8 35 ± 7 0.75
Diabetes, % 25 (28) 9 (19) 16 (36) 0.093
Hypertension, % 60 (67) 29 (67) 30 (68) 0.83
Renal disease, % 21 (23) 10 (24) 11 (25) 0.85
CHA2DS2VASc, mean (SD) 3.5 ± 1.5 3.3 ± 1.6 3.7 ± 1.7 0.32
ICD/CRTD, % 2 (2) None 2 (4) 0.49
Pacemaker 11 (12) 5 (11) 6 (15) 0.74
ACE Inhibitor or ARB, % 47 (52) 22 (46) 25 (60) 0.64
Aldosterone, % 10 (11) 4 (9) 6 (15) 0.74
Beta-blocker, % 67 (74) 30 (63) 37 (88) 0.04
Calcium channel blocker, % 25 (28) 12 (26) 13 (29) 0.81
Digitalis, % 6 (7) 2 (4) 4 (9) 0.67
Amiodarone, % 60 (67) 30 (63) 30 (69) 0.83
Flecainide, % 20 (22) 10 (21) 10 (23) 0.79
Propafenone, % 5 (6) 4 (9) 1 (2) 0.36
Statins, % 39 (43) 21 (46) 18 (42) 0.56
NOAC, % 66 (73) 33 (69) 33 (76) 0.47
Warfarin, % 24 (27) 14 (30) 10 (23) 0.41
Creatinine, mean (SD), mg/dl 1 ± 0.3 1 ±0.3 0.9 ± 0.3 0.32
K , mean (SD), mg/dl 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 0.73
Na , mean (SD), mg/dl 140 ± 4 140 ± 3 140 ± 2 0.49
Mg , mean (SD), mg/dl 2 ± 0.4 2± 0.2 2 ± 0.4 0.94